| | Case 1 | Case 2 | Case 3 |
| | Gender | Male | Male | Female | | Age (years) | 27 | 67 | 29 | | Etiology of HF | Becker muscular dystrophy | Ischemic heart disease | Chagas’ heart disease | | Onset of PRES symptoms (days) | 6 | 5 | 58 | | Symptoms | Decreased visual acuity, generalized tonic-clonic seizures, altered level of consciousness | Blurred vision generalized tonic-clonic seizures, altered level of consciousness | Blurry vision generalized tonic-clonic seizures, altered level of consciousness, severe headache | | Previous drugs | Tacrolimus MMF, methylprednisolone, TMP/SMX, acyclovir, vancomycin | Tacrolimus MMF, methylprednisolone, TMP/SMX, acyclovir, vancomycin, ceftriaxone | Tacrolimus MMF, prednisone, TMP/SMX, acyclovir, diltiazem, losartan | | Hemoglobin (mg/dl) | 9.0 | 10 | 8.5 | | Leukocytes (cel/ml) | 6,470 | 8,540 | 14,130 | | Platelets (cel/ml) | 130,000 | 140.000 | 441,000 | | Creatinine (mg/dl) | 0,9 | 0,8 | 0,88 | | Sodium (mEq/l) | 141 | 139 | 135 | | Potassium (mEq/l) | 3.9 | 4.0 | 5.97 | | Glycemia (mg/dl) | 138 | 165 | 145 | | Tacrolimus (ng/dl) | 2.6 | 8.9 | 17.4 | | Brain MR | Bilateral and symmetrical parietal and occipital cortical-subcortical hyperintensities in the FLAIR and T2 sequences (Figure 1) | Asymmetric cortical hyperintensities in the parietal and occipital lobes (Figure 2) | Hyperintense lesions of posterior cortical and subcortical predominance without abnormal enhancements with the contrast agent (Figure 3) | | Management | Discontinuing tacrolimus, starting cyclosporine, levetiracetam | Discontinuing tacrolimus, starting cyclosporine, levetiracetam | Discontinuing tacrolimus, starting cyclosporine, levetiracetam | | Recurrence of symptoms at 6 months | None | None | None |
|
|
